OCGN Key Statistics, Chart & Performance
The current stock price of OCGN is 1.16 USD. In the past month the price decreased by -24.36%. In the past year, price increased by 35.63%.
OCGN Latest News, Press Relases and Analysis
OCGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.83 | 397.94B | ||
| AMGN | AMGEN INC | 15.56 | 183.19B | ||
| GILD | GILEAD SCIENCES INC | 15.14 | 153.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.03 | 110.24B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.52 | 78.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 914.71 | 61.63B | ||
| INSM | INSMED INC | N/A | 44.15B | ||
| NTRA | NATERA INC | N/A | 32.82B | ||
| BIIB | BIOGEN INC | 10.77 | 26.45B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.07 | 20.53B | ||
| INCY | INCYTE CORP | 15.85 | 19.98B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About OCGN
Company Profile
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 95 full-time employees. The company went IPO on 2014-12-03. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. The company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. The company is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Company Info
OCUGEN INC
11 Great Valley Parkway
Malvern PENNSYLVANIA 19355 US
CEO: Shankar Musunuri
Employees: 95
Phone: 14843284701
OCUGEN INC / OCGN FAQ
What does OCGN do?
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 95 full-time employees. The company went IPO on 2014-12-03. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. The company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. The company is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
What is the stock price of OCUGEN INC today?
The current stock price of OCGN is 1.16 USD. The price decreased by -1.69% in the last trading session.
Does OCGN stock pay dividends?
OCGN does not pay a dividend.
What is the ChartMill rating of OCUGEN INC stock?
OCGN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Would investing in OCUGEN INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on OCGN.
Can you provide the number of employees for OCUGEN INC?
OCUGEN INC (OCGN) currently has 95 employees.
When does OCUGEN INC (OCGN) report earnings?
OCUGEN INC (OCGN) will report earnings on 2026-03-03, after the market close.
OCGN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to OCGN. When comparing the yearly performance of all stocks, OCGN is one of the better performing stocks in the market, outperforming 88.3% of all stocks.
OCGN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to OCGN. Both the profitability and financial health of OCGN have multiple concerns.
OCGN Financial Highlights
Over the last trailing twelve months OCGN reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS decreased by -29.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -111.15% | ||
| ROE | -1812.06% | ||
| Debt/Equity | 8.04 |
OCGN Forecast & Estimates
11 analysts have analysed OCGN and the average price target is 9.18 USD. This implies a price increase of 691.38% is expected in the next year compared to the current price of 1.16.
For the next year, analysts expect an EPS growth of -12.74% and a revenue growth 4.2% for OCGN